Signals flagged in the original
Analyzed by our bias model Full breakdown ↓
The FDA's advisory committee voted unanimously to support the approval of Moderna's mRNA flu vaccine, mRNA-1010, on June 18, 2026. Trials indicated that the vaccine is more effective than standard flu shots and produces stronger immune responses in older adults.
Our neutral summary
The FDA's advisory committee voted unanimously to support the approval of Moderna's mRNA flu vaccine, mRNA-1010, on June 18, 2026. Trials indicated that the vaccine is more effective than standard flu shots and produces stronger immune responses in older adults.
The reporting belongs to Ars Technica; we don't reproduce it.
No note attached
on this article.
FDA advisors unanimously vote to approve Moderna's mRNA after agency drama
FDA Advisors Support Approval of Moderna's mRNA Flu Vaccine